Merck Raises Revenue Forecasts Amid Acquisition-Driven Profit Dip

The company adjusted its 2026 revenue outlook to a range of $66.3 billion to $67.3 billion, signaling confidence in its pipeline. However, the financial reality of its aggressive expansion strategy is reflected in the bottom line. Merck now anticipates adjusted earnings between $2.66 and $2.76 per share, a significant reduction from the prior forecast of $5.04 to $5.16 per share. This downward revision accounts for a $5.7 billion charge from the Terns deal and a $9 billion expense from the January purchase of Cidara Therapeutics.

Merck is currently navigating a pivotal transition as it faces looming patent expirations for key blockbusters, including the immunotherapy drug Keytruda in 2028 and diabetes treatments Januvia and Janumet. Keytruda remains the company’s primary engine, contributing $8.37 billion in quarterly sales, bolstered by the introduction of a new injectable version. Growth is also emerging elsewhere: Winrevair, a treatment for a rare lung condition, saw sales climb 75% to $588 million, while the Capvaxive vaccine generated $184 million. These gains underscore a strategic pivot toward replenishing revenue streams through both high-stakes acquisitions and the rapid scaling of new medical assets.